Immunicum’s patent application regarding the Company’s core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S.

  • 08:54

The United States Patent and Trademark Office (USPTO), has issued a notice of allowance regarding patent application 11/603,819 and thus intends to approve Immunicum’s patent application to protect the Company’s core-technology in the U.S. market.

Comments are closed.